China National Accord Medicines Corporation Ltd. engages in the retail and distribution of pharmaceutical products in China and internationally. The company off...
HBM Holdings enters strategic biologics R&D collaboration with Sinopharm
Sinopharm declares final dividend of RMB 0.69 a share for FY2025
Sinopharm Accord's Wind ESG rating has been upgraded to A, with a comprehensive score of 7.18, leading the ratings in the healthcare providers and services industry
Sinopharm Seeks Shareholder Mandate for Up to 10% H-Share Buyback
CICC Keeps Their Buy Rating on Sinopharm Group Co (SHTDF)
CLSA Raises Sinopharm TP to HKD25, Maintains Outperform